Table. Industry Payments to Physicians and Prescribing of Brand-Name Gabapentinoids, 2014-2016.
| Variable | Payments Associated With Brand-Name Gabapentinoidsa | Likelihood of Prescribing Brand-Name Gabapentinoids | ||
|---|---|---|---|---|
| No.(%) | Total Amount $, (%) | Incidence Rate Ratio (95% CI) | P Value | |
| General payments | 509 874 (100) | 11 453 810.87 (100) | 1.91 (1.87-1.96) | <.001 |
| Payment by physician typeb | ||||
| Generalists | 316 372 (62.0) | 3 733 357.02 (32.6) | 1.70 (1.64-1.76) | <.001 |
| Pain medication specialists | 148 119 (29.1) | 6 564 296.51 (57.3) | 2.76 (2.60-2.92) | <.001 |
| Other | 45 383 (8.9) | 1 156 157.34 (10.1) | 2.41 (2.27-2.56) | <.001 |
| Payment type | ||||
| Food and beverages, gifts, or educational materials | 486 322 (95.4) | 5 312 708.99 (46.4) | 1.91 (1.87-1.96) | <.001 |
| Speaker fees, consulting fees, honoraria, travel costs, or non-research grants | 23 552 (4.6) | 6 150 192.22 (53.7) | 1.30 (1.25-1.36) | <.001 |
a
Lyrica (pregabalin; Pfizer), Gralise (gabapentin; Assertio Therapeutics), and Horizant (gabapentin; Arbor Pharmaceuticals).
b
Types are categorized as generalists (family medicine, general practice, internal medicine, pediatrics, and obstetrics and gynecology), pain medication specialists (anesthesiology, neuromusculoskeletal medicine, pain medicine, psychiatry and neurology, and pain-related physical medicine and rehabilitation), and other.